Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
37 hedge funds and large institutions have $8.96M invested in Sio Gene Therapies Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 13 reducing their positions, and 8 closing their positions.
18% more capital invested
Capital invested by funds: $7.62M → $8.96M (+$1.33M)
8% less funds holding
Funds holding: 40 → 37 (-3)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
54% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$649K |
| 2 |
Morgan Stanley
New York
|
+$487K |
| 3 |
NM
Newtyn Management
New York
|
+$487K |
| 4 |
JC
JBF Capital
Aspen,
Colorado
|
+$139K |
| 5 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$95.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
-$1.66M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$469K |
| 3 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
-$349K |
| 4 |
CIA
Cladis Investment Advisory
Billings,
Montana
|
-$130K |
| 5 |
CC
Clearline Capital
New York
|
-$46.3K |
SIOX Hedge Fund Activity: Q4 2022 in Review
37 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q4 2022, worth a combined $8.96M — up 18% from $7.62M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of SIOX and 6 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 6 added.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $649K. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $1.66M sold.
- 37 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q4 2022, down from 40 in Q3 2022.
- Funds reported $8.96M of Sio Gene Therapies Inc. Common Stock stock for Q4 2022, up 18% quarter-over-quarter.
- 6 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q4 2022 and 8 closed out, a net change of -2 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q4 2022 was Tang Capital Management, an estimated $649K added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q4 2022 was Suvretta Capital Management, an estimated $1.66M sold.
Based on aggregated 13F filings for Q4 2022.